Kura Oncology, Inc. (NASDAQ:KURA – Get Free Report) COO Kathleen Ford sold 3,668 shares of Kura Oncology stock in a transaction dated Tuesday, September 29th. The shares were sold at an average price of $10.75, for a total value of $39,431.00. Following the transaction, the chief operating officer directly owned 142,986 shares in the company, valued at approximately $1,537,099.50. This trade represents a 2.50% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.
Kathleen Ford also recently made the following trade(s):
- On Monday, September 28th, Kathleen Ford sold 6,906 shares of Kura Oncology stock. The stock was sold at an average price of $10.50, for a total transaction of $72,513.00.
Kura Oncology Stock Up 1.9%
Shares of KURA stock traded up $0.20 during trading on Tuesday, hitting $10.81. 1,890,260 shares of the company were exchanged, compared to its average volume of 1,673,937. The company has a debt-to-equity ratio of 0.12, a quick ratio of 4.71 and a current ratio of 4.73. The firm has a market capitalization of $961.66 million, a price-to-earnings ratio of -3.21 and a beta of 0.44. The business’s 50-day simple moving average is $11.22 and its 200 day simple moving average is $10.15. Kura Oncology, Inc. has a twelve month low of $7.36 and a twelve month high of $13.90.
Key Kura Oncology News
Here are the key news stories impacting Kura Oncology this week:
- Positive Sentiment: KO-7246 regenerated functional pancreatic beta-cell mass and improved glycemic control in Type 1 and Type 2 diabetes models. Benefits persisted for at least one month after treatment stopped in a Type 1 diabetes model, suggesting potential disease-modifying activity. KO-7246 EASD announcement
- Positive Sentiment: The candidate increased beta-cell mass, endogenous insulin and C-peptide levels, and showed enhanced activity when combined with semaglutide. Results in human pancreatic islets also indicated selective beta-cell proliferation and improved glucose-responsive insulin secretion, strengthening the potential commercial value of Kura’s menin-inhibitor platform. KO-7246 preclinical data
- Neutral Sentiment: KO-7246 remains preclinical. Caspian plans IND-enabling work and a future Phase 1 study, with management scheduled to discuss the program on October 13. Any valuation benefit for KURA therefore depends on future clinical progress and the terms of Kura’s relationship with Caspian. Caspian and Kura KO-7246 report
- Negative Sentiment: Several Kura executives and insiders sold shares on September 28–29, including Mollie Leoni, Brian Powl, Kathleen Ford, Thomas Doyle and Teresa Bair. The transactions totaled approximately 97,000 shares and more than $1 million, signaling near-term insider selling pressure even though the sellers retained substantial holdings. Kura insider ownership filing
- Negative Sentiment: The diabetes opportunity carries substantial execution risk, including potential clinical or regulatory setbacks, unexpected safety findings and the need for additional financing before human trials can begin.
Analysts Set New Price Targets
A number of equities analysts have recently weighed in on the stock. Sanford C. Bernstein set a $24.00 price target on shares of Kura Oncology in a research note on Monday, June 15th. Cantor Fitzgerald reissued an “overweight” rating on shares of Kura Oncology in a research report on Thursday, June 4th. Weiss Ratings restated a “sell (d-)” rating on shares of Kura Oncology in a research note on Friday, July 17th. Raymond James Financial set a $24.00 target price on Kura Oncology in a research report on Monday, August 24th. Finally, Citigroup reiterated a “market outperform” rating on shares of Kura Oncology in a report on Monday, August 24th. Ten equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $25.40.
View Our Latest Report on KURA
Institutional Investors Weigh In On Kura Oncology
A number of large investors have recently bought and sold shares of KURA. BlackRock Inc. acquired a new position in Kura Oncology during the second quarter worth $115,286,000. Bank of America Corp DE acquired a new stake in shares of Kura Oncology in the second quarter worth about $12,735,000. Connor Clark & Lunn Investment Management Ltd. acquired a new stake in shares of Kura Oncology in the second quarter worth about $10,927,000. Man Group plc bought a new stake in shares of Kura Oncology during the 2nd quarter worth about $4,749,000. Finally, Pale Fire Capital SE boosted its stake in shares of Kura Oncology by 89.6% during the 1st quarter. Pale Fire Capital SE now owns 857,474 shares of the company’s stock worth $6,971,000 after acquiring an additional 405,229 shares in the last quarter.
Kura Oncology Company Profile
Kura Oncology, Inc is a biopharmaceutical company focused on developing precision medicines for the treatment of cancer. The company’s research programs target specific genetic and molecular abnormalities that contribute to tumor growth, with an emphasis on hematologic malignancies and selected solid tumors.
Kura’s leading program has been ziftomenib, an oral, selective menin inhibitor being developed for genetically defined forms of acute myeloid leukemia, including cancers with NPM1 mutations or certain KMT2A rearrangements.
Featured Articles
- Five stocks we like better than Kura Oncology
- CarMax Just Gave Investors a Better Reason to Believe in the Turnaround
- CoreWeave Comes With Risks: Analysts Split on What Matters Most
- Bottlenecking the Future: TSMC Prices Out the Competition
- Fervo Energy Hits Geothermal Milestone: Will It Matter For The Stock?
Receive News & Ratings for Kura Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology and related companies with MarketBeat.com's FREE daily email newsletter.
